By Christian Moess Laursen

AstraZeneca said Wednesday that trial results showed that its Tagrisso drug in combination with chemotherapy demonstrated strong improvement for patients with lung cancer

The Anglo-Swedish pharmaceutical company said the FLAURA2 Phase 3 trial was for progression-free survival--the length of time a patient lives with a disease without it getting worse--for patients with epidermal growth factor receptor-mutated, non-small cell lung cancer.

For the moment, the overall survival data--the length of time from the start of diagnosis or treatment that the patient is still alive--were still immature and will be formally assessed at a subsequent analysis, AstraZeneca said.

"These significant FLAURA2 results show Tagrisso has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing," Executive Vice President of the company's Oncology R&D Susan Galbraith said.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

May 17, 2023 03:06 ET (07:06 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Set 2023 até Out 2023 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Out 2022 até Out 2023 Click aqui para mais gráficos Astrazeneca.